FDA Releases Q&A on ANDAs and Stability Testing
FDA clarifies stability data recommendations for abbreviated new drug applications.
FDA has released answers to questions received during the public comment period for the draft guidance document Stability Testing of Drug Substances and Products,Questions and Answers, published in the Federal Register on September 25, 2012 as well as responses to comments received on the draft of this guidance published in the Federal Register on August 27, 2013. The Q&A document responds to concerns regarding drug master files (DMFs), drug product manufacturing and packaging, and stability studies.
In the Q&A document, FDA clarifies the stability testing data recommendations for abbreviated new drug applications (ANDAs). According to the Q&A document, “the stability guidance covers all new ANDAs under the Federal Food, Drug, and Cosmetic Act, section 505 (j), and DMFs (Type II for drug substances that support the ANDAs). It does not apply to postapproval changes.”
FDA addresses questions related to the timing and amount of accelerated stability and long-term stability data required for an ANDA, intermediate stability study requirements, stability bracketing and matrixing, shelf-life calculation requirements, sample storage times, and more.
Source: FDA.gov
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
